Exhibit 99.1

Contact:

Chuck Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

FOR IMMEDIATE RELEASE

             ORAGENICS ANNOUNCES FIRST CLOSING ON PRIVATE PLACEMENT

ALACHUA, FL (NOVEMBER 30, 2004): Oragenics, Inc. (AMEX:ONI) announced today that
it has made a first closing on a Private Placement of unregistered Units (common
shares and warrants) for proceeds totaling $687,500. The company sold 250,000
shares at a price of $2.75 per share, with each share receiving one-half a
warrant for the purchase of additional shares at $3.50 per share.

The purpose of the private placement is to raise funds to support the clinical
development of the company's various technologies and for general corporate
purposes.

Neither the Units, nor the shares of Common Stock underlying the Units or the
warrants included in the Units, are registered under the Securities Act of 1933,
as amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy in any jurisdiction.

ABOUT ORAGENICS

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay, which is anticipated to enter clinical trials in early 2005. The
company is also developing a novel antibiotic with broad-spectrum activity
against gram-positive bacteria and a probiotic product aimed at maintaining oral
health. The company is headquartered in Alachua, Florida. For more information
about Oragenics, please consult the company's website at www.oragenics.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995: This release includes forward-looking statements which reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions which do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;)4) the ability to develop commercial products with the in-licensed
technology; and (5)) other factors detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.

                                       ###